Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2019 08:00 ET | Source: Immutep Limited

Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer

NEW YORK, July 09, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “Company”), an Australian biotechnology company developing novel immunotherapy treatments for...
June 25, 2019 08:00 ET | Source: Immutep Limited

Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer

226 patients with metastatic breast cancer have been enrolled in the AIPAC studyCombination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with...
June 24, 2019 14:36 ET | Source: Immutep Limited

Immutep to Host Key Opinion Leader Call

NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and...
June 21, 2019 08:00 ET | Source: Immutep Limited

Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy

SYDNEY, Australia, June 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
June 13, 2019 08:00 ET | Source: Immutep Limited

Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial

Recruitment for 2nd line (PD-1 refractory) NSCLC and 2nd line HNSCC cohorts of the TACTI-002 trial, conducted in collaboration with MSD, are ongoingInitial data from the TACTI-002 study expected...
June 06, 2019 08:00 ET | Source: Immutep Limited

INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”

Highlights First patient received first dose in INSIGHT-004, a phase I clinical trialEvaluates the combination of eftilagimod alpha with avelumab (BAVENCIO®) in different cancer indicationsPatient...
June 03, 2019 08:00 ET | Source: Immutep Limited

Immutep Presentation at ASCO 2019

SYDNEY, Australia, June 03, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
May 23, 2019 08:00 ET | Source: Immutep Limited

Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy

SYDNEY, Australia, May 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
May 17, 2019 08:00 ET | Source: Immutep Limited

Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

Presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 SYDNEY, Australia, May 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP)...
May 10, 2019 08:00 ET | Source: Immutep Limited

Immutep Announces Upcoming Industry Conference Participation

SYDNEY, Australia, May 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...